Marie Varloteaux

Yaounde, CE, Cameroon

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Durability of the Efficacy and Safety of Dolutegravir-Based and Low-Dose Efavirenz-Based Regimens for the Initial Treatment of Human Immunodeficiency Virus Type 1 Infection in Cameroon: Week 192 Data of the NAMSAL-ANRS-12313 Study.

Durability of the Efficacy and Safety of Dolutegravir-Based and Low-Dose Efavirenz-Based Regimens for the Initial Treatment of Human Immunodeficiency Virus Type 1 Infection in Cameroon: Week 192 Data of the NAMSAL-ANRS-12313 Study.

Journal: Open forum infectious diseases

Published: August 23, 2023

Improvements in Patient-Reported Outcomes Following Initiation of Dolutegravir-Based or Low-Dose Efavirenz-Based First-Line Antiretroviral Therapy: A Four-Year Longitudinal Analysis in Cameroon (NAMSAL ANRS 12313 Trial).

Improvements in Patient-Reported Outcomes Following Initiation of Dolutegravir-Based or Low-Dose Efavirenz-Based First-Line Antiretroviral Therapy: A Four-Year Longitudinal Analysis in Cameroon (NAMSAL ANRS 12313 Trial).

Journal: Journal of acquired immune deficiency syndromes (1999)

Published: January 16, 2023

Large Diffusion of Severe Acute Respiratory Syndrome Coronavirus 2 After the Successive Epidemiological Waves, Including Omicron, in Guinea and Cameroon: Implications for Vaccine Strategies.

Large Diffusion of Severe Acute Respiratory Syndrome Coronavirus 2 After the Successive Epidemiological Waves, Including Omicron, in Guinea and Cameroon: Implications for Vaccine Strategies.

Journal: Open forum infectious diseases

Published: December 06, 2022

Rapid Increase of Community SARS-CoV-2 Seroprevalence during Second Wave of COVID-19, Yaoundé, Cameroon.

Rapid Increase of Community SARS-CoV-2 Seroprevalence during Second Wave of COVID-19, Yaoundé, Cameroon.

Journal: Emerging infectious diseases

Published: April 26, 2022

Research priorities for accelerating the achievement of three 95 HIV goals in Cameroon: a consensus statement from the Cameroon HIV Research Forum (CAM-HERO).

Research priorities for accelerating the achievement of three 95 HIV goals in Cameroon: a consensus statement from the Cameroon HIV Research Forum (CAM-HERO).

Journal: The Pan African medical journal

Published: August 04, 2021

Outcomes of the first meeting of the CAMEROON HIV RESEARCH FORUM (CAM-HERO).

Outcomes of the first meeting of the CAMEROON HIV RESEARCH FORUM (CAM-HERO).

Journal: The Pan African medical journal

Published: August 03, 2021

Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial).

Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial).

Journal: PharmacoEconomics

Published: November 20, 2020

Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon.

Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon.

Journal: The lancet. HIV

Published: June 08, 2020

Ethics of health research partnerships in Global South : PhD students in learning.

Ethics of health research partnerships in Global South : PhD students in learning.

Journal: Medecine et sante tropicales

Published: June 29, 2017

Communities and vulnerability to HIV: a review of research among men having sex with men in Senegal

Communities and vulnerability to HIV: a review of research among men having sex with men in Senegal

Journal: Medecine et sante tropicales

Published: May 22, 2014

Hospital care for a child living with HIV in Dakar. What is the cost for the family?

Hospital care for a child living with HIV in Dakar. What is the cost for the family?

Journal: Bulletin de la Societe de pathologie exotique (1990)

Published: April 02, 2013

Showing 1-11 of 11

Last Updated: 09/26/2026